PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
Liang Y, Luo H, Li X, Liu S, Habib A, Liu B, Huang J, Wang J, Yi H, Hu B, Zheng L, Xie J, Zhu N.
Liang Y, et al. Among authors: zheng l.
Front Immunol. 2024 Apr 30;15:1367040. doi: 10.3389/fimmu.2024.1367040. eCollection 2024.
Front Immunol. 2024.
PMID: 38745661
Free PMC article.